Cognitive Preservation & Performance
Protecting the Asset That Governs Everything
Both of my parents developed Alzheimer’s disease. I watched cognitive decline take two brilliant, accomplished people — each with decades of sharp, disciplined thinking behind them. That experience is why brain health receives more of my clinical attention than perhaps any other domain — and why I don’t wait for symptoms to begin working on it.
The Risk Most People Miss
The brain does not fail suddenly. It erodes. By the time a patient notices the word-finding difficulty, the processing lag, the memory gaps — structural change is already advanced, often by a decade or more.
This is where most medicine fails. It waits for a reason to act. By then, the window for meaningful intervention has narrowed significantly.
Cognitive preservation is built into this practice from day one — not added when symptoms appear.
Eight Drivers of Cognitive Decline
Neurodegeneration is not purely genetic. It is driven by metabolic, vascular, hormonal, and lifestyle factors — most of which are measurable and modifiable. The eight primary drivers, each monitored and managed in this practice:
Insulin Resistance
Impairs neuronal glucose uptake; accelerates amyloid accumulation
Neuroinflammation
Chronic microglial activation drives synaptic loss
Cardiovascular Deconditioning
Reduced cerebral perfusion; lower BDNF; smaller hippocampal volume
Muscle Loss
Loss of myokine signaling that directly stimulates neurogenesis
Sleep Disruption
Impairs glymphatic clearance; beta-amyloid and tau accumulate
Hormonal Decline
Estrogen, testosterone, and progesterone are central to brain architecture
Omega-3 Deficiency
DHA is structural to every neuron; EPA resolves neuroinflammation
Chronic Cortisol Elevation
Measurable hippocampal volume loss; the same drive that builds businesses creates sustained sympathetic activation
What the Program Does
Every one of these drivers is measured and managed as part of the standard protocol. Cognitive preservation is not a separate module — it is built into the metabolic, hormonal, cardiovascular, and sleep architecture of the entire model.
Cognitive performance is tracked longitudinally using validated assessment tools. ApoE genotype is tested — genetic risk status informs the urgency and precision of every strategy applied. CNS Vital Signs baseline and annual reassessment define trajectory, not just current status.
Clinical Depth
Dr. Rosenbloom serves on the Medical Advisory Board of the Alzheimer’s Treatment Centers of America and participates as a clinical investigator in emerging neurodegenerative therapies — including investigational agents available through FDA Expanded Access pathways. This proximity to the research frontier means his patients benefit from what he learns there, before it reaches standard care.